Influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B
10.3760/cma.j.issn.1003-9279.2010.05.014
- VernacularTitle:阿德福韦酯对慢性乙型肝炎患者HBV特异性CTL的影响
- Author:
Yu-Lin ZHOU
1
;
Xue-Cai WANG
;
Yin-Tao WU
;
Yong-Fei TAN
;
Yan-Ping ZHAO
;
Jun-Ming TANG
;
Jian-Qiang PAN
Author Information
1. 宜兴市人民医院
- Keywords:
Adefovir dipivoxil;
Hepatitis B,Chronic;
Hepatitis B viras;
T-Lymphocytes,cytotoxic
- From:
Chinese Journal of Experimental and Clinical Virology
2010;24(5):362-363
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the influence of adefovir dipivoxil on HBV specific CTL in patients with chronic hepatitis B (CHB). Methods 10 mg adefovir dipivoxil (Zhengda Tianjing Pharmaceutical Company) was used for CHB patients with positive HBV DNA (HBV DNA ≥ 1 × 104 copies/ml) ,ALT ＞ 2 × upper limit of normal value (ULN) and positive human leucocyte antigen (HLA)-A2,orally,once a day for 3 months. Real time fluorescent quantitative PCR was used to determine HBV DNA and flowcytometer was used to determine HBV specific CTL. Results After treatment with adefovir dipivoxil for 3 months, HBV specific CTL (0. 52 ± 0. 11 )% was higher than that before treatment(0. 34 ± 0. 14 )% , t =6.78 P ＜0. 01, HBV DNA of 28 cases turned to negative ( ＜ 1 × 103copies/ml) (62. 22% ). HBV DNA of 17 cases failed to turn negative 3 months after treatment,but their HBV DNA level was lower [(4. 18 ±0.4)log 10 copies/ml] than that before treatment [(6. 23 ± 0. 73 ) log 10 copies/ml], t = 9.99, P ＜ 0.01.Conclusion adefovir dipivoxil can improve HBV specific cellular immunity in patients CHB.
